LATS1 and bladder transitional cell carcinoma: CircXRN2 activates Hippo pathway by stabilizing LATS1, inhibiting glycolytic activity in bladder cancer (BLCA) cells and reducing lactate production, which leads to the inhibition of H3K18 lactylation modifications, subsequently inhibiting the progression of BLCA [12].